Espinosa-Oliva Ana M, García-Miranda Pablo, Alonso-Bellido Isabel María, Carvajal Ana E, González-Rodríguez Melania, Carrillo-Jiménez Alejandro, Temblador Arturo J, Felices-Navarro Manuel, García-Domínguez Irene, Roca-Ceballos María Angustias, Vázquez-Carretero María D, García-Revilla Juan, Santiago Marti, Peral María J, Venero José Luis, de Pablos Rocío M
Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de, Sevilla, Spain.
Departamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Front Pharmacol. 2021 Aug 18;12:706439. doi: 10.3389/fphar.2021.706439. eCollection 2021.
Parkinson's disease is a highly prevalent neurological disorder for which there is currently no cure. Therefore, the knowledge of risk factors as well as the development of new putative molecular targets is mandatory. In this sense, peripheral inflammation, especially the originated in the colon, is emerging as a predisposing factor for suffering this disease. We have largely studied the pleiotropic roles of galectin-3 in driving microglia-associated immune responses. However, studies aimed at elucidating the role of galectin-3 in peripheral inflammation in terms of microglia polarization are lacking. To achieve this, we have evaluated the effect of galectin-3 deletion in two different models of acute peripheral inflammation: intraperitoneal injection of lipopolysaccharide or gut inflammation induced by oral administration of dextran sodium sulfate. We found that under peripheral inflammation the number of microglial cells and the expression levels of pro-inflammatory mediators take place specifically in the dopaminergic system, thus supporting causative links between Parkinson's disease and peripheral inflammation. Absence of galectin-3 highly reduced neuroinflammation in both models, suggesting an important central regulatory role of galectin-3 in driving microglial activation provoked by the peripheral inflammation. Thus, modulation of galectin-3 function emerges as a promising strategy to minimize undesired microglia polarization states.
帕金森病是一种高度流行的神经系统疾病,目前尚无治愈方法。因此,了解风险因素以及开发新的潜在分子靶点至关重要。从这个意义上说,外周炎症,尤其是起源于结肠的炎症,正成为患这种疾病的一个诱发因素。我们在很大程度上研究了半乳糖凝集素-3在驱动小胶质细胞相关免疫反应中的多效性作用。然而,缺乏旨在阐明半乳糖凝集素-3在小胶质细胞极化方面在外周炎症中的作用的研究。为了实现这一目标,我们在两种不同的急性外周炎症模型中评估了半乳糖凝集素-3缺失的影响:腹腔注射脂多糖或口服葡聚糖硫酸钠诱导的肠道炎症。我们发现,在外周炎症状态下,小胶质细胞数量和促炎介质的表达水平特异性地出现在多巴胺能系统中,从而支持帕金森病与外周炎症之间的因果联系。在两种模型中,半乳糖凝集素-3的缺失都显著降低了神经炎症,这表明半乳糖凝集素-3在驱动由外周炎症引发的小胶质细胞激活中具有重要的中枢调节作用。因此,调节半乳糖凝集素-3的功能成为一种有前景的策略,可将不期望的小胶质细胞极化状态降至最低。